Overview of Amfotericina B

This foundational section defines the core identity and purpose of Amfotericina B (Amphotericin B), highlighting its unique characteristics as a critical antifungal agent.

Property	Description
Active ingredient	Amphotericin B
Primary Form	Intravenous (IV) preparation (e.g., liposomal, colloidal dispersion)
Pharmacological Class	Polyene macrolide, Antifungal Agent
General Purpose	Treatment of severe systemic fungal infections (mycoses)
Origin	Natural product (derived from Streptomyces nodosus)

Amfotericina B: Definition and Pharmacological Identity

Amfotericina B (Amphotericin B) is a powerful, foundational antimicrobial agent that belongs to the polyene macrolide class of antifungal agents. It is primarily classified as a single-entity product reserved for serious, deep-seated infections. Amphotericin B is used to treat life-threatening fungal infections in patients. This clinically recognized medication is critical for treating a wide spectrum of fungal pathogens.

Composition, Origin, and Preparation Types

The active ingredient, Amphotericin B, is a natural product derived from the soil bacterium Streptomyces nodosus, making its origin biological rather than fully synthetic. For administration, the medication is formulated exclusively as an intravenous (IV) preparation to ensure direct systemic availability. This agent is effective against numerous yeast and mold species, establishing it as a critically important drug.

Amfotericina B is available in multiple forms, including the original conventional formulation and modern lipid-based systems, such as the liposomal formulation and colloidal dispersion. These modern systems encapsulate the active compound within a protective lipid vehicle. The development of lipid formulations was key to improving the drug's safety profile.

The Role of Amfotericina B in Severe Infections

The general purpose of Amfotericina B is to provide broad-spectrum fungicidal activity necessary to eliminate progressive fungal infections and life-threatening mycoses. It functions by directly targeting and disrupting the integrity of the fungal cell membrane, which leads to the irreversible killing of the pathogen. This potent mechanism means the medication is principally reserved for treating patients, such as those who are severely immunocompromised due to conditions like chemotherapy or organ transplantation, where less aggressive treatments may prove ineffective against rapidly spreading fungal diseases.

Regulatory References

What side effects are possible with Amfotericina B?

Possible Side Effects and Safety Information

Amfotericina B's safety profile is formally structured by government regulatory documents, classifying adverse reactions by frequency and the body systems affected. This framework establishes the constraints and required patient monitoring for its use in severe fungal infections.

Very Common Adverse Reactions (Affecting more than 1 in 10 patients):

Regulatory labeling highlights expected adverse effects such as infusion-related reactions, including pyrexia (fever) and chills/rigors, often occurring during or shortly after the initial infusion. Nephrotoxicity (kidney damage), indicated by increased serum creatinine, is also classified as a very common and dose-limiting concern. Disturbances in body chemistry, such as Hypokalemia (low potassium), are frequently observed.

System-Organ Classification and Serious Concerns

The most impacted body systems, as per official classification, are Renal and Urinary Disorders and Metabolism and Nutrition Disorders. Common adverse reactions include anemia and headache. While less frequent (Uncommon), the official safety profile documents serious adverse events such as cardiac arrest and seizures.

Safety Considerations and Limitations

The risk of nephrotoxicity is generally noted to be related to the cumulative dose and the total duration of treatment. Safety information requires caution and close monitoring for patients with pre-existing renal impairment or severe hepatic impairment. The medicine is generally contraindicated in individuals with a known hypersensitivity to Amphotericin B.

Overdose and Emergency Response

Overdose and When to Seek Help

Official government regulatory bodies classify overdosage of Amphotericin B as an event that may result in potentially fatal outcomes, specifically cardiac arrest or cardiopulmonary arrest. Therefore, if an overdose is suspected, it is mandated that patients or caregivers seek immediate medical attention and contact emergency services without delay.

Overdose Risk and Prevention

Official prescribing information documents a critical risk factor for overdosage: the potential for a medication error involving the confusion between the conventional Amphotericin B formulation and the modern lipid-based preparations. This formulation confusion has been associated with a risk of fatal overdose. To prevent this inadvertent overdosage, regulators strictly mandate that the product name and dose be verified prior to administration. The total daily dose of the conventional formulation is formally constrained to not exceed 1.5 mg/kg body weight.

Management and Monitoring Requirements

There is no specific antidote known for Amphotericin B overdosage. Therefore, management consists entirely of symptomatic and supportive treatment under close medical supervision. The official label requires close monitoring of several vital organ systems and parameters. This includes continuous observation of renal function, hepatic function, and hematopoietic function. Additionally, management protocols require laboratory monitoring of serum electrolytes, specifically levels of potassium and magnesium. These actions define the necessary regulatory response to an overdose situation.

Therapeutic Uses of Amfotericina B

Amphotericin B is an antifungal medication primarily used to manage serious fungal infections. The medicine is commonly used in clinical scenarios to address conditions caused by systemic fungal pathogens that have spread throughout the body, often affecting patients who are immunocompromised. Its main uses and benefits stem from its capacity to help manage the symptoms associated with these infections.

The core benefit the patient receives is the relief of symptoms caused by fungal diseases such as pneumonia, sepsis, and meningitis. Amphotericin B is indicated for a wide range of serious mycoses, including aspergillosis, candidiasis, cryptococcosis, North American blastomycosis, coccidioidomycosis, histoplasmosis, paracoccidioidomycosis, and mucormycosis.

Quick Fact: Relief for Invasive Fungal Symptoms

“Amphotericin B is often an initial step in managing invasive fungal infections.”

Eligibility and Restrictions for Use

Who Can and Cannot Use Amfotericina B

Official regulatory documents define strict criteria for eligibility based on patient status, age, and existing medical conditions.

Eligibility Scope

Classification	Population	Status
Contraindicated	Patients with known hypersensitivity to Amphotericin B or a component of the formulation.	Explicitly prohibited, unless the fungal infection is life-threatening and only amenable to this therapy.
Not Recommended	Patients with clinically inapparent fungal disease (e.g., confirmed only by serologic tests).	Must not be used for non-progressive, non-fatal fungal infections.
Not Established	Infants under one month of age (liposomal formulation).	Safety and efficacy have not been established in this age group.
Restricted Use	Pregnant women.	Should only be used if the potential benefits to the mother outweigh the potential risks to the fetus.
Restricted Use	Lactating/Breastfeeding women.	Use is generally not recommended; a decision must be made to discontinue nursing or discontinue the drug.
Conditional Use	Patients with pre-existing renal impairment.	The less toxic lipid-based formulations are often indicated specifically when renal impairment precludes the use of conventional Amphotericin B.

Official Eligibility Statements:

The product is contraindicated in patients with documented hypersensitivity to Amphotericin B.
The safety and efficacy have not been established in infants under one month old.
Conventional Amphotericin B should be used with care in patients with reduced renal function.

Connection to the overall eligibility profile: The regulatory profile establishes absolute contraindications (hypersensitivity) and defines specific populations where use is restricted or not established (infants, pregnancy, lactation). Eligibility often requires careful assessment of a patient's renal function to determine which formulation is appropriate, as stated in the prescribing information.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Amfotericina B primarily by additive toxicities and mandatory administration constraints.

Pharmacodynamic and Toxicity Interactions

Interacting Agents	Official Regulatory Description
Other Nephrotoxic Medications (e.g., Cyclosporine, Aminoglycosides)	May enhance the potential for drug-induced renal toxicity (additive nephrotoxicity).
Corticosteroids, ACTH, and Digitalis Glycosides	Amphotericin B-induced hypokalemia may potentiate the toxicity of these co-administered agents.
Antineoplastic Agents	May enhance the potential for renal toxicity, hypotension, and bronchospasm.
Flucytosine	Its toxicity is increased due to possible impaired renal excretion and/or increased cellular uptake.
Azoles / Imidazoles (e.g., Ketoconazole)	Studies suggest a potential for fungal resistance; caution is specified, especially in immunocompromised patients.

Administration Constraints and Timing Rules

Co-administration with leukocyte transfusions has been associated with reports of acute pulmonary toxicity, leading to the recommendation that these infusions be separated by as long a period as possible. Furthermore, the liposomal formulation is physically incompatible and must not be mixed with saline solutions, other electrolytes, or other medicinal products for infusion, except those specified for preparation. No clinically significant interactions with food, alcohol, or herbal products are explicitly documented in official labeling.

Mechanism of Action

How Amfotericina B Works

Amphotericin B achieves its fungicidal action through a dual mechanism primarily focused on the fungal cell membrane and the induction of cellular stress.

️ Targeted Fungal Cell Membrane Destruction

This mechanism centers on the drug's high-affinity binding to ergosterol, the unique sterol component of the fungal membrane, which is largely absent in human cells. This targeted interaction causes Amphotericin B molecules to self-associate and form ion-permeable pores that physically breach the fungal barrier. The key physiological consequence is the rapid and massive efflux of essential cations (K^+, Mg^2+) from the cell, causing immediate depolarization and catastrophic loss of osmotic integrity. This physical collapse halts critical internal enzyme functions, representing the mechanism for its fungicidal activity.

Complementary Oxidative Stress and Synergy

Complementary to membrane disruption, Amphotericin B acts as a prooxidant, driving the formation of Reactive Oxygen Species (ROS) inside the fungal cell. This secondary mechanism generates widespread oxidative damage to the cell's internal components, which contributes to the irreversible destruction of the pathogen. Mechanistically, this drug also acts as a permeabilizing agent; when used alongside an antifungal partner like flucytosine, its membrane disruption facilitates the partner drug's entry, resulting in increased intracellular accumulation of the partner drug.

Dosage and Administration Information

How to Use Amphotericin B

Amphotericin B, available in conventional (deoxycholate) and lipid complex/liposomal forms, must be administered strictly by slow intravenous (IV) infusion. It is forbidden to administer this medicine by mouth, intramuscular injection, or rapid IV bolus.

Dosing and Schedule

Frequency: The medicine is given once daily.
Dosing Rule: The dose is calculated based on the patient’s body weight (in kilograms) and typically begins with a test dose or a low starting dose, which is then gradually increased as prescribed.
- For conventional amphotericin B deoxycholate, the initial dose is often 0.25 to 0.3 mg/kg per day, slowly escalating up to a maximum of 1.5 mg/kg per day.
- Liposomal formulations generally have a higher starting dose, such as 3.0 to 5.0 mg/kg per day.
Infusion Time: Administration must be slow. Conventional formulations are typically infused over 2 to 6 hours. Liposomal formulations are generally infused over 30 to 60 minutes, which may be extended for doses greater than 5 mg/kg.

Preparation Requirements

This medicine is a lyophilized powder that requires specific steps for preparation:

Reconstitution: The vial must be reconstituted using Sterile Water for Injection (without a bacteriostatic agent).
Dilution: The reconstituted concentrate must be further diluted only with 5% Dextrose Injection (Glucose). Saline solutions (NaCl) are not compatible with the final infusion solution.
Final Concentration: The infusion solution must fall within a specific concentration range, typically 0.1 to 2.0 mg/mL depending on the formulation.

Special Procedural Notes

Dose Verification: The specific product name (e.g., deoxycholate vs. liposomal) and the calculated dose must be verified immediately prior to administration to prevent accidental errors.
Interruption: If treatment is interrupted for seven days or more, therapy must be restarted at the lowest recommended initial dose.

Recent Clinical Evidence

Research evidence / Overview of studies for Amfotericina B

This section outlines the types of official research—such as randomized controlled trials (RCTs) and systematic reviews—that have been conducted for Amfotericina B. It describes the study populations and the specific outcomes researchers monitored to understand how this medicine was evaluated in clinical settings.

Evidence for Use in Systemic Candidiasis

The evidence landscape for Amfotericina B was studied for use in systemic yeast infections and includes a large number of Randomized Controlled Trials (RCTs). Studies primarily examined adults with bloodstream infections, designed to measure endpoints such as all-cause mortality and the rate of fungal clearance. Research exploring comparative study designs indicated that the original conventional form and the modern lipid-based preparations showed comparable measurements of microbiological outcomes.

Research on Cryptococcal Meningitis

Amfotericina B was evaluated in a substantial number of foundational and modern RCTs for fungal infections of the central nervous system, particularly cryptococcal meningitis. The research focused heavily on combination therapy regimens and the main populations studied were adults living with HIV infection. Research examined the rate of Early Fungicidal Activity—a measurement of how quickly the fungus was cleared from the cerebrospinal fluid (CSF)—alongside all-cause mortality. This research was primarily based on foundational and modern RCTs.

Evidence Gaps and Areas of Research Uncertainty

Research involving invasive aspergillosis often involved systematic reviews in severely immunocompromised adults. However, the overall evidence base still presents several research limitation frames. Long-term effects are not fully established, as follow-up durations were limited in many trials. Data for certain specific groups, such as those with highly complex comorbidities, remain insufficient. The results apply only to the populations studied in the specific conditions under which the research was conducted.

Frequently Asked Questions (FAQ)

Common questions about Amfotericina B (FAQ)

Q: What types of fungal infections is Amphotericin B approved to treat?

Official labeling indicates Amphotericin B is approved to treat severe, progressive fungal infections. This includes life-threatening conditions such as invasive aspergillosis, cryptococcal meningitis, candidiasis, and blastomycosis. It is designated for patients whose condition meets specific criteria outlined in the regulatory label.

Q: What is the difference between Amphotericin B and liposomal Amphotericin B?

The key difference between the conventional and liposomal formulations is in the safety profile. Official information states that lipid-based versions were developed to be less toxic to the kidneys (less nephrotoxic) and to potentially reduce the severity of infusion-related reactions, such as fever and chills.

Q: Can Amphotericin B be used in children?

Regulatory information shows that Amphotericin B is used in children. There is no specific data to suggest that its effects or side effects are significantly different in children compared to adults, though individual factors always require close monitoring.

Q: What kind of kidney monitoring is necessary when taking Amphotericin B?

Because of the risk of kidney damage, or nephrotoxicity, regulatory documents indicate that frequent monitoring of renal function is necessary while receiving this medication. Additionally, official instructions advise monitoring the patient's blood counts and electrolyte levels (such as potassium and magnesium).

Q: Is Amphotericin B considered a 'strong' or 'last resort' medication?

Official regulatory documents restrict the use of this drug primarily to patients with progressive, potentially life-threatening fungal infections. The medication is generally not recommended for treating non-invasive or less serious fungal infections in individuals with normal immune function.

Q: Does Amphotericin B affect liver function?

Official product information advises that liver function should be monitored on a regular basis during therapy with Amphotericin B. This is done to check for potential changes in liver chemistry over the course of the treatment.

Q: What happens if a dose of Amphotericin B is missed?

If the treatment is interrupted for seven days or longer, official procedural notes indicate that therapy is typically restarted at the lowest initial recommended dosage level. The dose is then increased gradually as initially prescribed.

Q: Is Amphotericin B a toxic drug?

Official safety documents indicate that Amphotericin B can cause serious side effects, including severe kidney damage (nephrotoxicity) and acute, potentially severe reactions during infusion. This is why its use is reserved for treating severe, life-threatening infections.

Q: What is the function of the deoxycholate formulation of Amphotericin B?

The conventional deoxycholate formulation uses a substance called deoxycholic acid to suspend the drug as a stable colloidal dispersion. This preparation method is necessary because Amphotericin B does not dissolve easily in water, allowing it to be administered intravenously.

Q: Can Amphotericin B affect blood pressure?

Yes, official documents list hypotension (low blood pressure) as a common acute reaction that can occur. This typically happens within one to three hours after starting the infusion.

Q: What should be avoided while using Amphotericin B?

Official regulatory documents describe the need to avoid using Amphotericin B simultaneously with other drugs known to be nephrotoxic (damaging to the kidneys), such as cyclosporine. It is also recommended to separate the timing of leukocyte (white blood cell) transfusions from the Amphotericin B infusion as much as possible due to the risk of acute lung problems.

Q: Does Amphotericin B affect the nervous system?

Effects on the nervous system have been reported in official documents. Headache is listed as a common effect, and less common or rare effects include seizures (convulsions) and conditions like peripheral neuropathy.

Q: Is Amphotericin B used in treating non-fungal infections?

Yes, regulatory information states that Amphotericin B is used for more than just fungal infections. It is also indicated for treating certain life-threatening protozoan infections, such as visceral leishmaniasis.

Q: Are the side effects of Amphotericin B usually temporary?

While renal function may return to normal after stopping the drug, official information indicates that permanent kidney damage can occur, particularly when high cumulative doses are used. The duration and reversibility of effects can vary based on individual factors.

Q: What are the signs of a serious reaction to Amphotericin B?

Signs that could indicate a serious reaction, according to official regulatory warnings, include breathing problems, hives or swelling of the face or throat, wheezing, decreased urination, and seizures.

Q: Can elderly patients take Amphotericin B safely?

Official documentation does not provide specific comparative safety data for the elderly population versus other age groups. However, older patients are often more likely to have underlying medical conditions that can increase their risk for the drug's inherent nephrotoxicity (kidney damage).

Q: Why does the treatment with Amphotericin B sometimes take a long time?

The overall length of treatment is determined by the site and severity of the infection and the patient’s clinical status. Depending on the disease, treatment courses can vary significantly, with some conditions, like aspergillosis, requiring therapy for many months.

Q: What is the typical length of time for Amphotericin B treatment?

Official guidelines state that the ideal treatment duration is not universally defined and must be individualized. The duration depends on the infection; for example, therapy for sporotrichosis may range up to nine months based on clinical evidence.

Q: Why is pre-medication sometimes given before Amphotericin B infusion?

Official prescribing information notes that medications like acetaminophen and antihistamines are often given prior to the infusion. This is done to help decrease the severity of common infusion-related reactions, such as fever, shaking chills, and headaches.

Q: Are there different brand names for Amphotericin B?

Yes, the active ingredient, Amphotericin B, is available under several different brand names globally. These include brand names such as AmBisome, Abelcet, and Fungizone.

Q: Can I receive Amphotericin B treatment at home?

Official patient information indicates that the medication may be administered in a hospital setting or, depending on the prescription and overall clinical plan, may be used at home. The decision depends on the treating physician’s assessment.

Q: Does Amphotericin B have a black box warning?

Yes, the conventional formulation of Amphotericin B carries a Boxed Warning (also called an Important Warning). This is a strong regulatory statement highlighting the drug's restricted use for potentially life-threatening infections and the risks associated with its serious side effects.

Q: Can Amphotericin B cause injection site reactions?

Yes, common local adverse reactions listed in official documents include injection site pain. This pain may be accompanied by inflammation of the vein (phlebitis) or blood clotting (thrombophlebitis).

How should Amfotericina B be stored and disposed of?

How to Store and Dispose of Amphotericin B: Official Requirements

Official regulatory documents define strict storage and disposal requirements for Amphotericin B.

Storage Environment and Conditions

The unmixed vials of the conventional formulation must be stored in a refrigerator at 2 C to 8 C (36 F to 46 F). The product must be protected from light and stored in its original container to maintain integrity. Freezing of the reconstituted or diluted solution is prohibited. The medicine must be kept out of the sight and reach of children.

Stability and Disposal

Reconstituted solutions have limited in-use stability, typically requiring use within a specified, short time frame, even if refrigerated. Any unused or expired product must be thrown away and disposal must be carried out in accordance with local pharmaceutical waste requirements.

Amfotericina B